Marta Arsuaga

Dr. Marta Arsuaga

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Infectious Diseases of Poverty
Verified
Journal Article
Open access
PDF file
SPSabino Puente
Sabino Puente
MLMar Lago
Mar Lago
MSMercedes Subirats
Mercedes Subirats
ISIsmael Sanz-Esteban
Ismael Sanz-Esteban
MAMarta Arsuaga
Marta Arsuaga
AMAntonio Muro
Antonio Muro
Background: Mansonella perstans infection can be considered one of the most neglected tropical infectious diseases. Very few studies have reported on the clinical picture caused by infection with this nematode. Therefore, our study was aimed to describe the clinical patterns and treatment of imported M. perstans infection by migrants from Africa. Methods: The present study evaluated a large cohort of migrants who have been diagnosed, examined and treated for imported M. perstans infection at a Spanish reference center (Hospital Carlos III Tropical Medicine Unit, Madrid, Spain) over a 19-year period. Most patients voluntarily attend the emergency unit or are referred from primary care or general hospitals in Madrid. Chi-square test was used to compare the association between categorical variables. The continuous variables were compared by Student’s t-test or the Mann–Whitney test. The corresponding regression models were used for multivariate analysis. Results: Five hundred three cases of migrants from tropical and subtropical areas with M. perstans infection were identified. Two hundred sixty-four patients were female (52.5%). The mean age (± SD) was 44.6 ± 18.2 years (range: 16–93 years). The mean time (± SD) between the arrival in Spain and the first consultation was 8.6 ± 18.0 months. The major origin of the patients was Equatorial Guinea (97.6%). Regarding the clinical picture, 257 patients were asymptomatic (54.7%) and 228 were symptomatic (45.3%); 190 patients had pruritus (37.8%), 50 (9.9%) had arthralgia, 18 patients had Calabar-like swelling (3.6%), and 15 (3%) had abdominal pain. Four hundred forty-two (87.9%) migrants had hyper-IgE, and 340 (67.6%) had eosinophilia. One hundred ninety-five patients had coinfections with other filarial nematodes (38.8%), and 308 migrants had only M. perstans infection (61.2%). Four hundred thirty-seven cases (86.9%) had been treated with anti-filarial drugs; 292 cases were treated with one anti-filarial drug, and 145 cases were treated with combined anti-filarial therapy. Additionally, 20 (4%) cases received steroids and 38 (7.6%) cases received antihistamines. Conclusions: A long series of M. perstans infections is presented in sub-Saharan immigrants whose data indicate that it should be included in the differential diagnosis in patients with pruritus or analytical alterations such as eosinophilia or hyper-IgE presentation, and they also have a high number of coinfections with other microorganisms whose treatment needs to be protocolized.

27 June 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
Fernando SalvadorFernando Salvador
Fernando Salvador
ADANA LUCAS DATO
ANA LUCAS DATO
SRSílvia Roure
Sílvia Roure
MAMarta Arsuaga
Marta Arsuaga
APAsunción Pérez-Jacoiste
Asunción Pérez-Jacoiste
Israel MolinaIsrael Molina
Israel Molina
Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.

8 March 2017 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
CTCarlos Toro
Carlos Toro
PTPatricia Trevisi
Patricia Trevisi
BLBeatriz López-Quintana
Beatriz López-Quintana
AAArancha Amor Aramendia
Arancha Amor Aramendia
NINuria Iglesias
Nuria Iglesias
MBMargarita Baquero
Margarita Baquero
Epidemiological data on dengue in Africa are still scarce. We investigated imported dengue infection among travelers with a high proportion of subjects from Africa over a 9-year period. From January 2005 to December 2013, blood samples from travelers with clinical suspicion of dengue were analyzed. Dengue was diagnosed using serological, antigen detection, and molecular methods. Subjects were classified according to birthplace (Europeans versus non-Europeans) and last country visited. Overall, 10,307 serum samples corresponding to 8,295 patients were studied; 62% were European travelers, most of them from Spain, and 35.9% were non-Europeans, the majority of whom were born in Africa (mainly Equatorial Guinea) and Latin America (mainly Bolivia, Ecuador, and Colombia). A total of 492 cases of dengue were identified, the highest number of cases corresponding to subjects who had traveled from Africa (N = 189), followed by Latin America (N = 174) and Asia (N = 113). The rate of cases for Africa (4.5%) was inferior to Asia (9%) and Latin America (6.1%). Three peaks of dengue were found (2007, 2010, and 2013) which correlated with African cases. A total of 2,157 of past dengue infections were diagnosed. Non-Europeans who had traveled from Africa had the highest rate of past infection (67.8%), compared with non-Europeans traveling from Latin America (38.7%) or Asia (35%). Dengue infection in certain regions of Africa is underreported and the burden of the disease may have a magnitude similar to endemic countries in Latin America. It is necessary to consider dengue in the differential diagnosis of other febrile diseases in Africa.

1 January 2022 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
MAMarta Arsuaga
Marta Arsuaga
MDMarta Díaz-Menéndez
Marta Díaz-Menéndez
FGFederico Giovanni Gobbi
Federico Giovanni Gobbi

22 September 2022 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
Fernando de la Calle-PrietoFernando de la Calle-Prieto
Fernando de la Calle-Prieto
MMMiriam Estébanez Muñoz
Miriam Estébanez Muñoz
GRGermán Ramírez
Germán Ramírez
MDMarta Díaz-Menéndez
Marta Díaz-Menéndez
MVMaría Velasco
María Velasco
FMFrancisco Javier Membrillo
Francisco Javier Membrillo

11 March 2024 in Travel Medicine and Infectious Disease
Verified
Journal Article
Open access
MAMarta Arsuaga
Marta Arsuaga
RBRosa De Miguel Buckley
Rosa De Miguel Buckley
FCFernando De La Calle-Prieto
Fernando De La Calle-Prieto
MDMarta Díaz-Menéndez
Marta Díaz-Menéndez
Detecting imported diseases by migrants and individuals visiting friends and relatives (VFR) is key in the prevention and management of emergent infectious diseases acquired abroad. Retrospective descriptive study on migrants and VFR from Central and South America between 2017 and 2022 attended at a National Referral Centre for Tropical Diseases in Madrid, Spain. Demographic characteristics, syndromes and confirmed travel-related diagnoses were obtained from hospital patient medical records. 1654 cases were registered, median age of 42 years, 69.1% were female, and 55.2% were migrants. Most cases came from Bolivia (49.6%), followed by Ecuador (12.9%). Health screening while asymptomatic (31.6%) was the main reason for consultation, followed by Chagas disease follow-up (31%). Of those asymptomatic at screening, 47,2% were finally diagnosed of any disease, mainly Chagas disease (19,7%) and strongyloidiasis (10,2%) CONCLUSION: Our study emphasizes the importance of proactive health screening to detect asymptomatic conditions in migrants and VFR, enabling timely intervention and improved health outcomes. By understanding the unique health profiles of immigrant populations, targeted public health interventions can be devised to safeguard the well-being of these vulnerable groups.